<article id="medrad" class="slide medrad has-subtitle" data-ag-name="MEDRAD Stellant CT Injection System page">

  <h2 class="slide-title">MEDRAD<sup class="reg">&reg;</sup> Stellant CT injection system<br>with Workstation</h2>
  <h3 class="slide-subtitle">An imaging system designed for reliability and ease-of-use</h3>

  <h4 class="slide-intro">The MEDRAD<sup class="reg">&reg;</sup> Stellant CT Injection System offers a scalable platform to provide<br> clinicians with tools to help improve efficiency, compliance and patient care.</h4>

  <div class="features-list">
    <ul>
      <li class="list-title">Features</li>
      <li><span class="plus-sign circle">&#43;</span><span>Integrated saline test with real-time<br>pressure monitoring</span></li>
      <li><span class="plus-sign circle">&#43;</span><span>Multi-phase programming</span></li>
      <li><span class="plus-sign circle">&#43;</span><span>Programmable pressure limit</span></li>
      <li><span class="plus-sign circle">&#43;</span><span>Dual-flow capabilities for cardiac imaging<br>and pulmonary angiography</span></li>
    </ul>
  </div>
  <div class="arrow-bubble">
    <div id="injections"></div>
    <div id="consumables"></div>
  </div>

  <div id="popup-text">
    <div class="popup-injections">
      <div class="popup-slides">
        <div class="popup-slide active-slide">
          <div class="header">
            <h3>Ultravist<sup class="reg">&reg;</sup></h3>
            <h4>An iodine based non-ionic monomeric low osmolar extracellular X-ray contrast medium (LOCM)</h4>
            <h5>Three different iodine concentrations to meet your clinical needs</h5>
          </div>
          <div id="injections-slide-one" class="slide-image">
            <p>
              Highest<br> 
              Canadian<br>
              approved<br>
              concentration<br>
              of 370 mg I/mL
            </p>
          </div>
          <div id="injection-measures">
            <div class="measure">
              <b>Ultravist<sup class="reg">&reg;</sup> 240</b><br>
              50 mL, 200 mL
            </div>
            <div class="measure">
              <b>Ultravist<sup class="reg">&reg;</sup> 300</b><br>
              50 mL, 100 mL,<br>
              150 mL, 500 mL
            </div>
            <div class="measure">
              <b>Ultravist<sup class="reg">&reg;</sup> 370</b><br>
              50 mL, 100 mL,<br>
              200 mL, 500 mL
            </div>
          </div>
        </div>

        <div class="popup-slide">
          <div class="header">
            <h3>Ultravist<sup class="reg">&reg;</sup></h3>
            <h4>A contrast media with reliable image quality<br>and proven safety</h4>
          </div>
          <div id="injections-slide-two" class="slide-image"></div>
          <div class="full-width slide-footer">
            <div>Ultravist<sup class="reg">&reg;</sup> balances osmolality, viscosity and iodine<br>concentration to allow for consistent delivery of high-quality CT images</div>
          </div>
        </div>

        <div class="popup-slide">
          <div class="text-slide">
            <p><b>INDICATIONS AND CLINICAL USE:</b> ULTRAVIST<sup class="reg">&reg;</sup> 240/300/370 Ultravist<sup class="reg">&reg;</sup> (iopromide) in its three strengths, is indicated for intravascular use to provide diagnostic information in a number of radiographic contrast procedures. It is also indicated for the visualization of various body cavities, eg., arthrography and hysterosalpingography. <b>Ultravist<sup class="reg">&reg;</sup> 240 Computed tomography (CT):</b> Peripheral arteriography (bifemoral pelvis/leg), Phlebography of the extremities, Arthrography, Hysterosalpingography, Cerebral Arteriography. <b>Ultravist<sup class="reg">&reg;</sup> 300 Computed tomography (CT):</b> Excretory urography, Pediatric excretory urography, Renal arteriography, Peripheral arteriography (bifemoral pelvis/leg), Cerebral arteriography, Phlebography of the extremities, Arthrography. <b>Ultravist<sup class="reg">&reg;</sup> 370 Computed tomography (CT):</b> Excretory urography, Coronary arteriography , (including PTCA), with or without left ventriculography, Pediatric angiocardiography, Arthrography *For information on the concentrations and doses for the Pediatric Population see Dosage and Administration and Use in Special Populations in the Full Prescribing Information.</p>
            <p><b>IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS:</b> Ultravist<sup class="reg">&reg;</sup> (iopromide) is not indicated for use in myelography, cerebral ventriculography, and cisternography. Ultravist<sup class="reg">&reg;</sup> should not be administered to patients with known hypersensitivity to the drug, or with manifest hyperthyroidism.</p>
            <p><b>SELECTED WARNINGS AND PRECAUTIONS:</b> Life-threatening or fatal anaphylactoid reactions may occur during or after Ultravist<sup class="reg">&reg;</sup> administration, particularly in patients with allergic disorders. Contrast media-induced nephrotoxicity, presenting as transient impairment of renal function, may occur after intravascular Ultravist<sup class="reg">&reg;</sup> administration. Patients with pre-existing renal impairment, diabetes mellitus, sepsis, hypotension, dehydration, cardiovascular disease, elderly patients, and patients with multiple myeloma, hypertension, patients on medications which alter renal function and patients with hyperuricemia, are at increased risk of this condition. Hemodynamic disturbances including shock and cardiac arrest may occur during or shortly after administration of Ultravist<sup class="reg">&reg;</sup>. Angiography may be associated with local and distal organ damage, ischemia, thromboembolism and organ failure. In angiographic procedures, consider the possibility of dislodging plaques or damaging or perforating the vessel wall with resultant pseudoaneurysms, hemorrhage at puncture site, dissection of coronary artery during catheter manipulations and contrast agent injection. The physicochemical properties of the contrast agent, the dose and the speed of injection can influence the reactions. Thyroid storm has occurred after the intravascular use of iodinated contrast agents in patients with hyperthyroidism, or with autonomously functioning thyroid nodule. Evaluate the risk in such patients before use of any iodinated contrast agent. Administer iodinated contrast agents with extreme caution in patients with known or suspected pheochromocytoma. Inject the minimal amount of contrast necessary. Contrast agents may promote sickling in individuals who are homozygous for sickle cell disease when administered intravascularly.</p>
            <p><b>MOST COMMON ADVERSE REACTIONS:</b> The most frequently observed adverse drug reactions (>4%) in patients receiving Ultravist<sup class="reg">&reg;</sup> are headache, nausea, and vasodilation.</p>
            <p><b>Please consult the Product Monograph at <a href="www.bayer.ca/ultravist">www.bayer.ca/ultravist</a> for important information relating to adverse reactions, drug interactions and dosing information.</b></p>
            <p><b>Reference: 1.</b> Palkowitsch PK, et al. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. Acta Radiol 2014;55(6):707–14.</p>         
          </div>
        </div>
      </div>
    </div><!-- .popup-injections -->

    <div class="popup-consumables">
      <div class="popup-slides">
        <div class="popup-slide active-slide">
          <div class="header">
            <h3>Consumables</h3>
            <h4>High-quality syringes to support reliable<br>system performance</h4>
            <h5 class="gray">Our syringes are designed and tested as part of an inter-related system to ensure<br>the fluid delivery performance with your MEDRAD® Stellant CT Injection System.</h5>
          </div>
          <div id="consumables-slide-one" class="slide-image"></div>
          <div class="features-list">
            <ul>
              <li><span class="plus-sign circle">&#43;</span><span>100% inspection for particulates</span></li>
              <li><span class="plus-sign circle">&#43;</span><span>Confirmed biological safety*</span></li>
              <li><span class="plus-sign circle">&#43;</span><span>Dependable system performance</span></li>
              <li><span class="plus-sign circle">&#43;</span><span>Automated precision crafting</span></li>
            </ul>
          </div>

          <div class="key"><sup class="astrix">*</sup> Bayer conducts analytical chemistry studies on finished products to ensure that our syringes fully meet medical biocompatibility requirements<br>and so do not contain any harmful substances.</div>
        </div>

        <div class="popup-slide">
          <h3>slide 2</h3>
          <div id="consumables-slide-two" class="slide-image"></div>
        </div>

      </div>
    </div><!-- .popup-injections -->
  </div>

</article>